FY2026 EPS Estimates for Transcat Lowered by Northland Capmk

Transcat, Inc. (NASDAQ:TRNS) – Equities researchers at Northland Capmk lowered their FY2026 earnings estimates for shares of Transcat in a report issued on Monday, December 16th. Northland Capmk analyst E. Jackson now forecasts that the scientific and technical instruments company will earn $1.92 per share for the year, down from their prior forecast of $2.42. The consensus estimate for Transcat’s current full-year earnings is $1.76 per share. Northland Capmk also issued estimates for Transcat’s FY2027 earnings at $2.19 EPS, FY2028 earnings at $2.50 EPS and FY2029 earnings at $2.86 EPS.

A number of other analysts have also weighed in on TRNS. Craig Hallum upped their target price on shares of Transcat from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $156.00 price objective on shares of Transcat in a research report on Tuesday, October 29th. Oppenheimer reaffirmed an “outperform” rating and set a $130.00 price objective (down from $155.00) on shares of Transcat in a research report on Wednesday, October 30th. StockNews.com downgraded shares of Transcat from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. Finally, Northland Securities cut their price target on Transcat from $130.00 to $110.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Transcat currently has a consensus rating of “Hold” and a consensus target price of $130.25.

Transcat Price Performance

TRNS stock opened at $106.78 on Thursday. The business’s 50-day moving average is $110.27 and its two-hundred day moving average is $118.87. The firm has a market capitalization of $982.27 million, a P/E ratio of 53.93 and a beta of 0.70. Transcat has a 1 year low of $94.29 and a 1 year high of $147.12.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings data on Monday, October 28th. The scientific and technical instruments company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.12). Transcat had a net margin of 6.63% and a return on equity of 7.36%. The company had revenue of $67.83 million during the quarter, compared to analyst estimates of $70.30 million. During the same quarter in the previous year, the business posted $0.41 earnings per share. The firm’s revenue was up 8.0% on a year-over-year basis.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Conestoga Capital Advisors LLC raised its stake in Transcat by 17.9% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 907,191 shares of the scientific and technical instruments company’s stock worth $109,561,000 after acquiring an additional 137,830 shares in the last quarter. Royce & Associates LP boosted its stake in Transcat by 8.2% in the third quarter. Royce & Associates LP now owns 511,701 shares of the scientific and technical instruments company’s stock valued at $61,798,000 after acquiring an additional 38,774 shares in the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Transcat by 22.1% during the third quarter. Champlain Investment Partners LLC now owns 409,500 shares of the scientific and technical instruments company’s stock worth $49,455,000 after purchasing an additional 74,169 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Transcat by 5.4% during the third quarter. Geode Capital Management LLC now owns 217,473 shares of the scientific and technical instruments company’s stock worth $26,269,000 after purchasing an additional 11,106 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Transcat by 8.1% in the 3rd quarter. State Street Corp now owns 207,230 shares of the scientific and technical instruments company’s stock valued at $25,027,000 after purchasing an additional 15,514 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.